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Abstract
Background: Smoking has been shown to reduce health-related quality of life (HRQOL) in patients with coronary
artery disease (CAD) undergoing percutanous coronary intervention (PCI) either by means of balloon angioplasty or
with the use of bare-metal stents (BMS). Drug-eluting stents (DES) have now been widely used and are related to
substantial reduction of restenosis and significantly improved HRQOL compared with BMS. This study aimed to
evaluate the effects of smoking on HRQOL in patients after PCI in DES era.
Methods: A cohort of 649 patients admitted for CAD and treated with drug-eluting stents were included in this
prospective, observational study. Patients were classified as non-smokers (n = 351, 54.1%), quitters (n = 126, 19,4%),
or persistent smokers (n = 172, 26.5%) according to their smoking status at the time they first admitted to hospital
and during the first year of follow-up. Each patient was prospectively interviewed at baseline, 6 months and 1 year
following PCI. HRQOL was assessed with the use of Medical Outcomes Study 36-Item Short-Form Health Survey
(SF-36).
Results: For the overall population, HRQOL scores at 1-year follow-up were significantly higher than baseline for all
8 domains. At 1-year follow-up, the HRQOL scores in persistent smokers were still lower than that in non-smokers in
6 domains except for bodily pain and mental health, and than that in quitters in 5 domains except for bodily pain,
role emotional and mental health. There were no significant differences with regard to the scores between
non-smokers and quitters except role emotional for which non-smokers had higher scores. After adjustment,
persistent smokers demonstrated significantly less improvements in HRQOL than non-smokers in 6 domains except
for bodily pain and social functioning and significantly less improvement than quitters for general health.
Improvements of quitters were comparable to that of non-smokers in all domains. Multivariate linear regression
analyses showed persistent smoking was an independent risk factor for PCS and MCS improvements.
Conclusions: Persistent smoking substantially diminishes the potential quality-of-life benefits of DES. Efforts should
be made to promote smoking cessation after DES implantation which could greatly improve the health quality
outcomes.
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Background
Coronary artery disease (CAD) has been the second
leading cause of death in the world including China.
This disease not only increases the mortality but also af-
fects the health-related quality of life (HRQOL) severely,
exerting negative effects on the energy and vitality levels,
social interactions and psychological aspects. Percutan-
eous coronary interventions (PCI) had been shown to ef-
fectively reduce mortality and morbidity in patients with
CAD [1]. The continued evolution of PCI techniques,
especially the introduction of using drug-eluting stents
(DES), has reduced the incidence of coronary restenosis
and the need for target vessel revascularization [2, 3].
Although considerable studies have been directed at
improving the outcomes of PCI, these studies have gen-
erally focused on “hard” end points such as death or
nonfatal myocardial infarction. In fact, HRQOL has also
played an very important role in the management of
CAD patients, which has been shown to predict adverse
clinical outcomes [4, 5]. Assessment of HRQOL and its
determinants may help bridge the gap between research
and clinical practice [6].
One of the most significant modifiable cardiovascular
determinants which is linked with poorer outcomes after
PCI is cigarette smoking. Previous studies have shown
that long-term risks of myocardial infarction and death
are higher in smokers than in nonsmokers after PCI [7].
However, the specific effects of cigarette smoking on
overall HRQOL after PCI especially with DES have not
been comprehensively studied. The purpose of this study
was to compare the effect of smoking on HRQOL in
patients with CAD treated with DES.
Methods
Study population
Consecutive patients with a discharge diagnosis of CAD
for the first time (including stable angina, unstable
angina and myocardial infarction with or without
ST-segment elevation) who underwent PCI with DES in
people’s hospital were enrolled between May 2011 and
November 2013. All patients received optimal medical
therapy. Patients were excluded if they refused to partici-
pate or if they were physically incapable of responding
to a questionnaire. Patients died in hospital or accom-
pany with other disease such as rheumatoid arthritis
which limit the physical activity were also excluded.
Evaluation of HRQOL
Researchers conducted chart reviews for each study
subject at the time of enrollment and HRQOL was
evaluated at baseline and at 6 and 12 months after revas-
cularization in patients treated with DES. The baseline
questionnaires were completed in hospital at the time of
the initial revascularization procedure, subsequent
questionnaires were sent by mail. Those patients who
did not respond to the mailed survey more than 2 weeks
were contacted by telephones. We relied on previously
validated questionnaire namely the Short-Form 36 (SF-
36) health survey [8] to assess the patients overall
healthy perception. This general HRQOL instrument
was chosen rather than more specific tools since it pro-
vides an assessment of subjects’ own perception of their
quality of life as a function of their general state of
health. SF-36 includes 36-item scales measuring the
following 8 health domains: physical functioning, role
limitations due to physical problems, bodily pain, general
health perceptions, vitality, social function, role limita-
tions due to emotional problems, and mental health, as
well as health change over the past year. Summary
scores are derived by collapsing the 8 subscales, each
scale ranges from 0 to 100, with a higher score corre-
sponding to a better HRQOL. The 8 specific domains of
physical and emotional scores can be summarized into 2
main scores: the Physical Component Score (PCS) and
Mental Component Score (MCS).
Smoking status evaluation
Smoking status was assessed on the basis of information
obtained from hospital medical records at the time of
first medical examination and rechecked by telephone
interview. All patients were classified as non-smokers,
quitters, or persistent smokers. Smokers were defined as
patients who had smoked cigarette for at least 1 year
and still smoked or at least smoking within 1 month
before baseline interview [9]. Non-smokers defined as
patients who had never smoked cigarettes regularly [10].
Patients who smoked before baseline interview and
continued smoking during the follow-up period were
considered persistent smokers. Patients who smoked
during the year before baseline interview but stopped
smoking during the follow-up period were considered
quitters. No patients in the study began smoking after
the index revascularization procedure or relapsed to
smoke after 1 year of abstinence.
Clinical follow-up
All patients received clinical follow-up at 1, 6 and
12 months after discharge to determine their symptom-
atic and clinical status. All end points including death,
recurrent myocardial infarction (MI), stroke or repeat
revascularization were recorded through direct patient
interview in a special outpatient clinic or by indirect
conversation with patients. Relatives had to be contacted
by phones for clinical events follow-up if patients died.
Statistical analysis
Continuous variables were expressed as mean ± SD and
differences among the three groups of patients were
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tested for significance with one-way analyses of variance.
Categorical variables were presented as counts and
frequencies and compared with Chi-square test or the
Fisher’s exact test.
A propensity score of probability in persistent smoking
was used to adjust for potential bias between these
groups. This was accomplished by performing a multi-
variable logistic regression analysis using persistent
smoking as the dependent variable and entering all
demographics, physical examination findings, clinical
presentation and medications that were likely to affect
the probability of persistent smoking. Stepwise backward
elimination was employed and the resultant independent
predictors of persistent smoking were then used to
calculate the probability of persistent smoking (propen-
sity score). By introducing the propensity score into
regression adjustment, the effect of persistent smoking
was estimated by adjustment for the impact of back-
ground covariates. The bias in the background covariates
between these three groups could be removed by adjust-
ments made with the propensity score [11, 12].
Multivariate linear regression models were created
to identify whether the mean change of quality of life
of persistent smokers differed from that of either
never smokers or quitters. Each regression model ad-
justed for demographic characteristics (age, sex, mari-
tal status), comorbid medical conditions
(hypertension, diabetes, hypercholesterolemia, congest-
ive heart failure, impaired renal function, history of
myocardial infarction), other clinical factors (number
of disease vessels, lesion type, total stent length, ejec-
tion fraction). The propensity score was forced into
all the models as covariate to balance the potential
bias. Multiple imputation strategy was employed to
account for missing scores which could potentially
produce selection bias from survey non-responders.
The results of sensitivity analysis using imputed data
were similar to analytic cohort and were not pre-
sented in this paper.
Statistical analyses were performed using SPSS 19.0 for
Windows (SPSS Inc, Chicago, Illinois). All tests of




A total of 785 consecutive patients were enrolled and
completed the baseline HRQOL instrument. 649 (82.7%)
finally completed the 1-year quality-of-life assessment
and were enrolled into our study for subsequent analysis.
Of them, 172 (26.5%) patients were persistent smokers,
351 (54.1%) patients were non-smokers and 126 (19.4%)
patients were quitters. Nineteen patients died before
1-year interview. There were no significant differences
between non-respondents and respondents in terms of
gender and most baseline characteristics except that
non-respondents were more likely to be younger
(60.04 years vs. 62.84 years, P = 0.005) and were less
likely to be married (78.7% vs. 87.2%, P = 0.011).
Baseline characteristics and angiographic features
Baseline characteristics and angiographic features of
these groups by smoking status were shown in Table 1.
Smokers were significantly younger and more male gen-
der than nonsmokers, and had higher body mass index.
Smokers also had more diabetes mellitus, hypertension
and prior acute myocardial infarction compared with
non-smokers. Left ventricular ejection fraction, labora-
tory test and medical treatment were similar between
smokers and non-smokers. There were no significant
differences in angiographic and PCI parameters between
these three groups.
Clinical follow-up
At 1-year follow-up, there were no significant differences
in the rates of recurrent myocardial infarction (1.7% for
persistent smokers, 1.1% for never smokers and 1.6% for
quitters, P = 0.734), target lesion revascularization (4.7%
for persistent smokers, 3.1% for never smokers and 3.2%
for quitters, P = 0.657), stroke (1.2% for persistent
smokers, 0.3% for never smokers and 0.8% for quitters,
P = 0.404) and any event (7.6% for persistent smokers,
4.6% for never smokers and 5.6% for quitters, P = 0.39)
between these three groups during the initial
hospitalization or the 1-year follow-up (data not shown
in Tables).
Health-related quality of life
For the overall population, HRQOL scores at 6-
month follow-up were significantly higher than base-
line for all 8 domains, with improvements ranging
from 4.0 points for mental health to 22.9 for role
physical. At 1-year follow-up, there were significantly
further improvements of 6 domains ranging from 1.3
points for mental health to 4.8 points for role
emotion than 6 months. The dimensions of health for
which scores did not improve significantly were
bodily pain and vitality (data not shown in Tables).
Table 2 and Fig. 1 showed the unadjusted life quality
scores at baseline, 6 months and 1 year by smoking sta-
tus. At baseline, the HRQOL was comparable between
these three groups except for general health, vitality and
role emotion, for which the non-smokers had higher
HRQOL than the other two groups. There were no
significant differences between the three groups in PCS
and MCS.
Compared to non-smokers and quitters, persistent
smokers had lower HRQOL scores at 6 months in 7
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domains except for mental health and in 6 domains
except for bodily pain and mental health separately.
After risk adjustment, persistent smokers improved to
a lesser extent than non-smokers in all the domains
and than quitters in 4 domains except for bodily pain,
social functioning, role emotion and mental health.
Quitters and nonsmokers had comparable improve-
ments on all SF-36 scales (Table 2).














Age (years) 60.27 ± 9.65 65.05 ± 9.32 60.21 ± 9.12 <0.001 <0.001 0.956 <0.001
Male n (%) 155 (90.1) 211 (60.1) 118 (93.7) <0.001 <0.001 0.277 <0.001
Marital status n (%) 147 (85.5) 310 (88.3) 114 (90.5) 0.405 0.356 0.195 0.509
Body mass index (kg/m2) 25.79 ± 2.80 25.12 ± 2.91 25.91 ± 2.74 0.005 0.011 0.739 0.008
Risk Factors n (%)
Diabetes mellitus 33 (16.9) 89 (25.4) 19 (15.1) 0.015 0.029 0.679 0.021
Hypertension 105 (61.0) 244 (69.5) 81 (64.3) 0.003 0.002 0.718 0.019
Hypercholesterolemia 55 (32) 126 (35.9) 44 (34.9) 0.674 0.376 0.594 0.844
Heart failure 16 (9.3) 25 (7.12) 11 (8.73) 0.808 0.529 0.865 0.712
Impaired renal dysfunction 6 (3.5) 15 (4.3) 4 (3.2) 0.858 0.667 0.882 0.588
Prior AMI n (%) 30 (17.4) 36 (10.3) 23 (18.3) 0.021 0.020 0.856 0.019
Unstable angina 117 (68.0) 221 (63.0) 82 (65.1) 0.521 0.225 0.594 0.672
Left ventricular ejection fraction 65.52 ± 6.93 65.38 ± 8.84 66.28 ± 8.43 0.577 0.86 0.435 0.299
In-hospital laboratory test
Fasting plasma glucose (mmol/L) 5.48 ± 1.55 5.77 ± 1.34 5.51 ± 1.26 0.170 0.125 0.477 0.229
Total cholesterol (mmol/L) 4.07 ± 0.88 4.21 ± 1.35 4.16 ± 0.87 0.422 0.190 0.522 0.651
Triglycerides (mmol/L) 1.67 ± 0.93 1.58 ± 1.15 1.75 ± 1.13 0.308 0.393 0.532 0.141
HDL cholesterol (mmol/L) 0.96 ± 0.19 0.99 ± 0.20 0.98 ± 0.14 0.136 0.046 0.319 0.505
LDL cholesterol (mmol/L) 2.43 ± 0.77 2.31 ± 0.82 2.44 ± 0.78 0.122 0.085 0.974 0.114
In-hospital treatments n (%)
Antiplatalet 172 (100) 351 (100) 126 (100) 1.000 1.000 1.000 1.000
Statins 169 (98.3) 348 (99.1) 123 (97.6) 0.441 0.370 0.699 0.187
ACEI/ARB 110 (64.0) 215 (61.3) 82 (65.1) 0.693 0.550 0.841 0.447
CCB 31 (18.0) 74 (21.1) 26 (20.6) 0.708 0.412 0.571 0.916
β-blockers 87 (50.6) 190 (54.1) 66 (52.4) 0.742 0.445 0.759 0.735
No. of diseased vessels n (%) 0.429 0.185 0.892 0.528
1 85 (49.4) 158 (45.0) 61 (48.4)
2 50 (29.1) 91 (25.9) 35 (27.8)
3 37 (21.5) 102 (29.1) 30 (23.8)
Reference vessel diameter (mm) 2.95 ± 0.42 3.01 ± 0.40 2.96 ± 0.34 0.213 0.100 0.732 0.277
Percentage diameter stenosis (%) 85.82 ± 12.31 84.61 ± 11.22 86.86 ± 11.55 0.146 0.260 0.446 0.062
B2/C class lesion n, (%) 129 (75.0) 253 (72.1) 99 (78.6) 0.344 0.480 0.472 0.155
Predilation n,(%) 148 (86.0) 299 (85.2) 111 (88.1) 0.722 0.793 0.604 0.420
Stent diameter (mm) 3.02 ± 0.41 3.08 ± 0.39 3.02 ± 0.34 0.104 0.074 0.982 0.104
Total stent length (mm) 32.18 ± 6.53 32.36 ± 7.00 33.56 ± 6.57 0.431 0.196 0.439 0.775
Stent delivery pressure (atm) 14.50 ± 2.31 14.39 ± 2.26 14.68 ± 2.05 0.435 0.583 0.487 0.202
Postdilation n,(%) 57 (33.1) 106 (30.2) 45 (35.7) 0.491 0.495 0.644 0.254
AMI acute myocardial infarction, HDL high density lipid, LDL Low density lipid, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers,
CCB calcium channel blockers
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At 1-year follow-up, the HRQOL scores in persistent
smokers were still lower than that in non-smokers in 6
domains except for bodily pain and mental health, and
than that in quitters in 5 domains except for bodily pain,
role emotional and mental health. There were no signifi-
cant differences with regard to the scores between non-
smokers and quitters except role emotional for which
non-smokers had higher scores. After adjustment, per-
sistent smokers demonstrated significantly less improve-
ment in HRQOL than non-smokers in 6 domains except
for bodily pain and social functioning and significantly
less improvement than quitters for general health. Im-
provements of quitters were comparable to that of non-
smokers in all domains. Improvement in PCS and MCS
also differed significantly according to smoking status
(Table 3).
Multivariate linear regression analyses showed that
age, persistent smoking, diabetic mellitus were the inde-
pendent risk factors for PCS improvement and age, per-
sistent smoker, marital status and diabetic mellitus were
Table 2 Unadjusted scores of health-related quality of life







3 Groups Persistent vs Never Persistent vs Quitter Never vs Quitter
Baseline
Physical functioning 69.87 ± 21.68 72.04 ± 23.36 72.24 ± 21.01 0.601 0.379 0.391 0.941
Role physical 34.33 ± 43.61 40.94 ± 41.15 32.65 ± 40.80 0.189 0.157 0.747 0.101
Bodily pain 61.25 ± 26.11 57.95 ± 27.93 63.38 ± 24.31 0.212 0.261 0.517 0.088
General health 43.33 ± 15.29 52.72 ± 16.50 52.28 ± 15.87 <0.001 <0.001 <0.001 0.820
PCS 52.20 ± 21.10 55.91 ± 21.65 55.14 ± 17.56 0.242 0.103 0.248 0.753
Vitality 62.26 ± 18.23 68.78 ± 19.17 65.91 ± 17.36 0.006 0.002 0.111 0.194
Social functioning 65.18 ± 22.67 70.02 ± 23.94 68.31 ± 20.70 0.157 0.056 0.268 0.531
Role emotional 45.33 ± 44.39 59.73 ± 45.99 45.32 ± 44.37 0.005 0.004 0.998 0.008
Mental health 67.6 ± 16.59 63.89 ± 15.99 67.61 ± 14.10 0.053 0.034 0.994 0.049
MCS 60.09 ± 20.73 65.60 ± 21.52 61.79 ± 19.43 0.050 0.017 0.511 0.126
6 months-baseline
Physical functioning 80.55 ± 15.81 86.92 ± 19.30 88.13 ± 16.46 <0.001 0.001 <0.001 0.559
Role physical 46.34 ± 39.78 63.43 ± 44.65 62.00 ± 42.07 0.001 <0.001 0.003 0.780
Bodily pain 80.12 ± 16.70 85.98 ± 19.51 82.02 ± 19.11 0.015 0.005 0.410 0.076
General health 38.74 ± 18.36 53.88 ± 19.23 54.13 ± 17.34 <0.001 <0.001 <0.001 0.910
PCS 61.44 ± 17.71 72.55 ± 20.36 71.57 ± 18.68 <0.001 <0.001 <0.001 0.669
Vitality 67.97 ± 18.25 77.72 ± 19.28 78.51 ± 18.46 <0.001 <0.001 <0.001 0.727
Social functioning 70.57 ± 21.28 79.79 ± 21.07 81.22 ± 0.98 <0.001 <0.001 <0.001 0.573
Role emotional 54.11 ± 38.37 81.30 ± 45.63 66.91 ± 44.09 <0.001 <0.001 0.017 0.005
Mental health 75.11 ± 16.08 76.55 ± 15.82 76.82 ± 15.97 0.623 0.417 0.389 0.888
MCS 66.69 ± 19.63 78.84 ± 20.88 75.62 ± 21.03 <0.001 <0.001 0.001 0.192
1 year-baseline
Physical functioning 81.43 + 16.95 89.19 ± 19.18 87.11 ± 16.32 <0.001 <0.001 0.010 0.328
Role physical 46.68 ± 39.75 64.67 ± 44.18 59.05 ± 41.39 0.001 <0.001 0.018 0.267
Bodily pain 80.37 ± 18.22 83.26 ± 17.36 83.32 ± 18.73 0.276 0.150 0.189 0.978
General health 41.13 ± 18.88 53.53 ± 19.06 54.87 ± 18.81 <0.001 <0.001 <0.001 0.555
PCS 62.40 ± 19.05 72.66 ± 20.31 71.09 ± 19.12 <0.001 <0.001 <0.001 0.054
Vitality 72.77 ± 20.83 82.72 ± 19.80 79.74 ± 19.63 <0.001 <0.001 0.006 0.218
Social functioning 77.73 ± 22.58 82.67 ± 21.02 83.49 ± 21.61 0.054 0.042 0.034 0.753
Role emotional 58.11 ± 37.48 78.72 ± 45.77 60.27 ± 39.42 <0.001 <0.001 0.675 <0.001
Mental health 78.89 ± 19.25 77.64 ± 16.65 77.84 ± 16.72 0.798 0.521 0.631 0.923
MCS 71.88 ± 21.67 80.44 ± 20.95 75.33 ± 19.51 0.001 <0.001 0.183 0.042
PCS physical component summary, MCS Mental component summary
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the independent risk factors for MCS improvement
(Table 4).
Discussion
This study reveals that PCI is associated with significant
improvements in most dimensions of health-related
quality of life at 1 year for the overall population in DES
era. However, even with DES implantation, persistent
smoker had substantially less improvements in health
status than non-smokers. Compared with persistent
smokers, those patients who quit smoking after DES
implantation had significantly greater improvements in
quality of life. Multivariate analysis showed that persist-
ent smoking was an independent risk factor for life
quality improvement.
Previous studies have evaluated the relationship be-
tween health status and PCI in patients with coronary
artery disease. Most studies, in which PCI was
performed with the use of either balloon angioplasty or
BMS, showed significant improvements of quality of life
Fig. 1 Unadjusted quality of life scores in 8 domains derived from SF-36 questionnaire according to smoking status
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Table 3 Adjusted changes in Health-Related Quality of Life according to smoking status







3 Groups Persistent vs Never Persistent vs Quitter Never vs Quitter
6 months-baseline
Physical functioning 10.72 ± 15.62 15.62 ± 17.71 16.29 ± 16.74 0.003 0.002 0.005 0.703
Role physical 13.35 ± 50.05 24.66 ± 47.76 26.44 ± 43.18 0.020 0.011 0.019 0.719
Bodily pain 18.78 ± 24.92 24.19 ± 28.63 19.15 ± 27.60 0.053 0.035 0.910 0.078
General health −4.86 ± 17.58 0.70 ± 14.57 2.49 ± 15.17 <0.001 <0.001 <0.001 0.268
PCS 9.50 ± 20.48 16.29 ± 19.91 16.09 ± 18.03 0.001 <0.001 0.004 0.922
Vitality 5.33 ± 16.09 9.68 ± 16.06 12.24 ± 14.92 0.001 0.003 <0.001 0.121
Social functioning 5.81 ± 21.19 10.92 ± 20.64 12.25 ± 24.70 0.015 0.011 0.554 0.554
Role emotional 8.31 ± 52.53 20.29 ± 50.33 19.72 ± 48.02 0.031 0.011 0.054 0.914
Mental health 7.28 ± 12.06 11.72 ± 15.34 9.72 ± 13.34 0.003 0.001 0.142 0.175
MCS 6.43 ± 20.00 13.15 ± 19.41 13.23 ± 17.94 <0.001 <0.001 0.003 0.968
1 year-baseline
Physical functioning 11.87 ± 15.87 17.46 ± 18.25 15.84 ± 17.37 0.003 0.001 0.053 0.183
Role physical 14.99 ± 50.07 27.38 ± 42.64 24.35 ± 43.83 0.013 0.003 0.076 0.517
Bodily pain 19.60 ± 27.07 22.54 ± 26.55 20.23 ± 25.66 0.433 0.235 0.840 0.402
General health −2.34 ± 17.09 0.81 ± 15.94 2.97 ± 16.26 0.017 0.039 0.006 0.203
PCS 11.03 ± 20.51 17.05 ± 18.20 15.85 ± 18.38 0.003 0.001 0.030 0.539
Vitality 10.14 ± 16.91 14.72 ± 16.51 13.31 ± 16.97 0.013 0.003 0.106 0.414
Social functioning 12.87 ± 21.62 14.30 ± 20.03 14.29 ± 25.53 0.760 0.477 0.577 0.994
Role emotional 11.86 ± 49.76 22.84 ± 50.93 12.98 ± 43.56 0.026 0.017 0.846 0.054
Mental health 10.79 ± 14.19 13.59 ± 16.15 10.49 ± 14.32 0.053 0.050 0.868 0.052
MCS 11.41 ± 20.88 16.36 ± 18.66 12.76 ± 17.77 0.013 0.006 0.546 0.070
PCS physical component summary, MCS Mental component summary
Table 4 Regression analysis for HRQOL Changes at 1 year
Variables PCS MCS
β 95% CI P value β 95% CI P value
lower upper lower upper
Age −0.262 −0.425 −0.099 0.002 −0.394 −0.555 −0.232 <0.001
Female 1.334 −2.497 5.184 0.492 1.061 −2.724 4.846 0.582
Marital status 1.141 −1.232 3.513 0.345 2.669 0.357 4.981 0.024
Persistent smoking −6.521 −12.039 −1.004 0.021 −9.378 −14.886 −3.871 0.001
Hypertension −2.616 −7.968 2.736 0.337 −1.872 −7.147 3.403 0.486
Diabetes Mellitus −5.689 −10.922 −0.456 0.033 −7.120 −12.274 −1.966 0.007
Hypercholesterolemia 2.795 −2.912 8.501 0.101 1.767 −3.917 7.451 0.542
Heart failure −0.281 −8.218 7.655 0.944 3.620 −4.201 11.442 0.364
Impaired renal dysfunction 3.875 −6.333 14.083 0.456 1.570 −8.415 11.554 0.758
Prior AMI −1.884 −5.649 1.880 0.326 2.797 −0.913 6.508 0.139
Multivessel disease −0.284 −6.567 5.999 0.929 −0.750 −6.942 5.443 0.812
Propensity Score −0.043 −0.098 0.011 0.120 −0.045 −0.099 0.009 0.103
HRQOL health-related quality of life, PCS physical component summary, MCS mental component summary, AMI acute myocardial infarction
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after the initial revascularization [13–16]. The revolu-
tionary use of DES has further remarkably reduced the
occurrence of restenosis thus the need of target lesion
revascularization during follow-up. Recent studies re-
vealed that PCI with DES could also improve the quality
of life. Cohen et al. compared the outcomes of CABG
with those of PCI with the use of DES among patients
with three-vessel or left main coronary artery disease,
and showed that both DES and CABG led to significant
improvements in disease-specific and general health sta-
tus over the course of 12 months [17]. van Domburg et
al. evaluated the HRQOL following SES implantation in
patients with multivessel disease and compared the out-
comes with historical surgical and BMS arms of the
ARTS-I study [18]. They found that along with a sub-
stantial reduction of restenosis, HRQOL after SES was
significantly improved as compared with BMS. Our
study, which was similar with previous studies, showed
HRQOL scores at 1-year follow-up were significantly
higher than baseline for the whole population after DES
implantation.
The impact of smoking on HRQOL in the general
population has been assessed by multiple cross-sectional
and retrospective studies which have found that smokers
tend to have worse quality of life than non-smokers [19,
20]. Several studies examined the relationship between
smoking status and HRQOL derived from a medical
intervention. Taira et al. evaluated the health status both
at the time of index procedure and the first year of
follow-up among 1432 patients including smokers, quit-
ters and nonsmokers who received PTCA, and demon-
strated that continued cigarette smoking has an adverse
impact on the improvement in quality of life [21]. Re-
cent study with a cohort of 2765 PCI patients by Jang et
al. showed that smokers at the time of PCI have worse
health status at 1 year than those who never smoked
[22]. Our study, focusing on the health status in the DES
era, showed that quality-of-life benefits brought by DES
implantation are diminished by persistent smoking.
Multivariate analyses showed that persistent smoking
was an independent risk factor for PCS and MCS
improvements.
The benefits of smoking cessation in patients with car-
diovascular disease, including those undergoing PCI
have been clearly established. The risks of adverse car-
diac events would diminish in patients with CAD with
smoking cessation and these benefits continued to in-
crease over time after quitting [23]. Critchley et al.
reviewed 20 studies with 12,603 smoking patients with
ischemic heart disease in a meta-analysis and docu-
mented that cessation of smoking after acute myocardial
infarction or cardiac surgery could significantly reduce
mortality [24]. Buchanan et al. evaluated the association
of smoking status with angina and HRQOL after acute
myocardial infarction (AMI) and found that smokers
who quitted after AMI had similar angina levels and
mental health as non-smokers [25]. In our study, about
42.3% of smokers quitted after DES implantation, who
have demonstrated significantly better improvement in
HRQOL than persistent smokers and comparable im-
provement with nonsmokers. These findings were con-
sistent with studies by Taira et al. and Jane et al. either
treated with PTCA or by PCI, in which smoking cessa-
tion was documented to be associated with better health
status outcomes [21, 22]. Considering the relatively low
proportion of smoking cessation, efforts to stop smoking
at the time of PCI should be made to improve the health
outcomes of these procedures. These data including ours
might supply further motivation for clinicians to stop
smoking in patients treated with DES.
Limitations
Our study has several limitations. The study is a single-
center trial and the size of the study is small, the
generalizability of our results is limited. Not all of the
eligible population completed follow-up quality-of-life
data. Only 82.7% of patients completed 1-year follow-up
assessment. This respondent rate compares favorably with
previous studies of quality-of-life outcomes. Non-
respondents in our studies had similar scores of HRQOL
with respondents at baseline. Treatment and adverse
event rates were also similar between respondents and
non-respondents. While interviewing patients’ relatives by
phones for clinical follow-up may impact on the validity
of the responses. Although adjustment for selection bias
using propensity score, other factors such as socioeco-
nomic factors and psychiatric conditions which may affect
decision making and multiple dimensions of both physical
and emotional health were not accounted for in this study.
Further larger multicenter studies with long term follow-
up should be needed to confirm these findings.
Conclusions
PCI with DES implantation substantially improved
HRQOL in patients with coronary artery disease,
whereas these potential benefits could be diminished by
persistent smoking. Patients who quit smoking after
DES implantation demonstrated significantly better
health status compared with persistent smokers. Efforts
should be made to stop smoking at the time of PCI in
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